ATB Therapeutics
Luxembourg, Belgium · Biotechnology, Therapeutics · 200 employees
ATB Therapeutics is a Belgium-based company developing a therapeutic antibody pipeline driven by its proprietary ATBioFarm platform. The company focuses on producing biologics with novel cell-killing mechanisms, aimed at improving effectiveness and safety compared to traditional treatments. ATB Therapeutics intends to use funding to expand its platform and accelerate the development of its weaponi
Funding history
- Series series a — $54.0M — Nov 2024
Recent signals
- May 19, 2026: ATB Therapeutics Appoints Mark Throsby as Chief Executive Officer
- Nov 18, 2024: Raised $54.0M in Series series a
See plans & pricing → Track ATB Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.